MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ijc.33212

Медицинская библиотека · International journal of cancer · 2020

Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.

Fan Fuli, Yoo Hyeon Joo, Stock Sophia, Wang Lei, Liu Yibin, Schubert Maria-Luisa, Wang Sanmei, Neuber Brigitte, Hückelhoven-Krauss Angela, Gern Ulrike, Schmitt Anita, Müller-Tidow Carsten, Dreger Peter, Schmitt Michael, Sellner Leopold

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Chimeric antigen receptor T (CART) cells targeting CD19 have shown promising results in the treatment of chronic lymphocytic leukemia (CLL). However, efficacy seems to be inferior compared to diffuse large B-cell lymphoma or acute lymphoblastic leukemia. Impaired T-cell fitness of CLL patients may be involved in treatment failure. Less-differentiated naïve-like T cells play an important role in CART expansion and long-term persistence in vivo. These cells are sparse in CLL patients. Therefore, optimization of CART cell production protocols enriching less differentiated T cell subsets may overcome treatment resistance. The B-cell receptor inhibitor ibrutinib targeting Bruton's tyrosine kinase (BTK) is approved for the treatment of CLL. Besides BTK, ibrutinib additionally inhibits interleukin-2-inducible T-cell kinase (ITK) which is involved in T-cell differentiation. To evaluate the effect of ibrutinib on CART cell production, peripheral blood mononuclear cells from nine healthy donors and eight CLL patients were used to generate CART cells. T-cell expansion and phenotype, expression of homing and exhaustion makers as well as functionality of CART cells were evaluated. CART cell generation in the presence of ibrutinib resulted in increased cell viability and expansion of CLL patient-derived CART cells. Furthermore, ibrutinib enriched CART cells with less-differentiated naïve-like phenotype and decreased expression of exhaustion markers including PD-1, TIM-3 and LAG-3. In addition, ibrutinib increased the cytokine release capacity of CLL patient-derived CART cells. In summary, BTK/ITK inhibition with ibrutinib during CART cell culture can improve yield and function of CLL patient-derived CART cell products.

Для цитирования: Fan Fuli, Yoo Hyeon Joo, Stock Sophia, Wang Lei, Liu Yibin, Schubert Maria-Luisa, Wang Sanmei, Neuber Brigitte, Hückelhoven-Krauss Angela, Gern Ulrike, Schmitt Anita, Müller-Tidow Carsten, Dreger Peter, Schmitt Michael, Sellner Leopold. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.. International journal of cancer. 2020. DOI: 10.1002/ijc.33212.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.